Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7670587 | 0.99 | LMNA (0.70) | LMNAGAAGRM4NPC1RAB9A | |
| SCHEMBL12197830 | 0.83 | GRM4 (1.00) | LMNAGAAGRM4NPC1RAB9A | |
| SCHEMBL7675914 | 0.83 | LMNA (0.65) | LMNAGAAGRM4NPC1RAB9A | |
| SCHEMBL4834530 | 0.82 | LMNA (0.74) | LMNAGAASMN1; SMN2MAPK1HPGD | |
| SCHEMBL12197835 | 0.81 | NPC1 (1.00) | LMNAGAAGRM4NPC1RAB9A | |
| SCHEMBL1972335 | 0.81 | NPC1 (0.74) | LMNAGAAGRM4NPC1RAB9A | |
| SCHEMBL7673748 | 0.80 | ALDH1A1 (0.74) | LMNAGAASMN1; SMN2PKM | |
| SCHEMBL7675575 | 0.80 | TP53 (0.65) | LMNAGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4829970 | 0.79 | MMP1 (0.67) | LMNAGAA | |
| SCHEMBL7674591 | 0.79 | LMNA (0.62) | LMNAGAASMN1; SMN2PKMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6403644-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | claimed |
| EP-0757037-A2 | Sulfonylamino acid derivatives as metalloproteinase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-05 | — | — | EP | claimed |